Business
Change of Director Particulars
Convatec Group Plc announced that Tobias Hestler, a Non-Executive Director, has been appointed to the board of Hikma Pharmaceuticals PLC as a non-executive director, effective August 7, 2026. This announcement is made in accordance with Listing Rule 6.4.9 and does not involve any financial figures for Convatec itself, as the company's 2025 revenues were over $2 billion and it is a constituent of the FTSE 100 Index. Disclaimer*
About this update from Convatec Group Plc
6 August 2026 Convatec Group Plc ("Convatec" or "the Company") Director Announcement London, UK, 6 August 2026 - In accordance with Listing Rule 6.4.9, Convatec confirms that Tobias Hestler, Non-Executive Director, has been appointed to the board of Hikma Pharmaceuticals PLC (LSE: HIK) as a non-executive director with effect from 7 August 2026. Contacts Company Secretariat: [email protected] Media: [email protected] Analysts & investors: [email protected] Convatec Group Plc's LEI code is 213800LS272L4FIDOH92 About Convatec Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com
View stock analysis, news, and events for Convatec Group Plc